immuno-onco-popup8

Cancer Target Rationale

TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a receptor expressed on various immune cells, including CD8+ and CD4+ T cells, NK cells, follicular T-helper cells, and regulatory T cells (Tregs).

TIGIT inhibits innate and adaptive immunity through multiple mechanisms, including suppressing T-cell activation and upregulating Tregs.1

Overview

GSK4428859A is an antagonist anti-TIGIT human IgG1 monoclonal antibody that has high affinity for TIGIT and engages Fcγ receptors.2

GSK4428859A is being investigated in selected advanced or metastatic cancers.3

References

  1. Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e000957. doi:10.1136/jitc-2020-000957.
  2. iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations. News release. BioSpace. June 14, 2021.
    https://us.gsk.com/en-us/media/press-releases/gsk-and-iteos-therapeutics-announce-development/
  3. ClinicalTrials.gov. Accessed September 21, 2021. www.clinicaltrials.gov/